Epiclear Acne Treatment Spray Proves Significant Efficacy in Clinical Trials

Tags:

September 2004 - Epiclear, The Clear Solution for Problem Skin, recently announced that the preliminary results of its independent clinical trial studies, conducted by Marshall-Blum, indicate significant improvement of overall acne problems in a triple blind, placebo controlled study. The results show that during the first 4 and 8 weeks of the trials, all major symptoms associated with acne were improved in the treated patient population with ongoing Epiclear treatment compared to the placebo group.

This makes Epiclear one of the only Over the Counter (OTC) acne medications to have conducted independent clinical trials to affirm efficacy.

"The results of the preliminary clinical trial studies confirm our confidence on Epiclear's efficacy. The testimonials we have received from tens of thousands of users across America are now further validated," says Eric Crouse, Epiclear product manager. "We are delighted that an independent clinical trial study has proven Epiclear's efficacy as one of the only OTC acne treatment products on the market today offering a one-step, easy to use, spray formula for acne treatment. This makes Epiclear The Clear Solution for Problem Skin.

"The product's active ingredient includes 0.5% salicylic acid - an FDA monographed active ingredient for acne treatment product - in addition to Phosphatidylcholine from Natural Lecithin, Glycerol and Vitamins A, C, and E, help soothe, moisturize, and heal the skin while treating the acne. Epiclear was recently featured on Boston's WCVB-TV, Channel 5 HealthBeat segment.

Consumers can obtain a FREE promotional bottle of Epiclear by calling 877-EPI-SKIN (877-374-7546) plus $12.95 Shipping & Handling charges in addition to an optional $5.00 charge for rush orders. Additional orders in continuity programs allow for volume savings, and time the shipments to match the supply. A six-bottle package is shipped every 85 days at $164.90, including priority shipping.

For more information visit www.epiclear.com.

SOURCE Epiclear